Best Life Sciences Platforms and Tools Companies in New Jersey, United States
The 74 best Life Sciences Platforms and Tools companies in New Jersey, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Veloxis.
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in New Jersey
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | Veloxis Transforming transplant medicine through innovative therapies and programs for healthcare providers | $60M | 100 mo ago | 54 | Mark Hensley Chief Executive Officer | — | — |
| 2 | Avalon Globocare Developer of diagnostics using exosome technology 21News top 26%Funding top 34%Patents top 45%Growth top 47% All 10 signals ▾Newstop 26% Fundingtop 34% Patentstop 45% Growthtop 47% Innovationbottom 48% Moatbottom 44% Globalbottom 40% Techbottom 36% Fin. healthbottom 26% Marketbottom 22% News: 14 BI events in 12 mo (of 21 tracked, 5 types) · 9 high-value events (IPO/M&A/funding/contracts) in 12 mo Funding: Raised $36.7M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 21/100 | $37M | 3 mo ago | 6 | — | 16 patents Engineered soluble protein fusions (GPCRs, CARs) and S‑layer emulsome delivery systems | — |
| 3 | Engage Therapeutics Inhaled drug-device combo as rescue treatment for uncontrolled epileptic seizures | $31M | 79 mo ago | 7 | — | — | — |
| 4 | Interpace Diagnostics Molecular diagnostics and pathology services for early cancer diagnosis and treatment | $27M | 83 mo ago | 120 | — | — | — |
| 5 | Cytosorbents Developer of hemoperfusion technology for removing toxins from the blood | $22M | 17 mo ago | 198 198 → 137 (-31%) | — | 216 patents Blood purification sorbents for removing toxins, cytokines, and potassium from plasma | — |
| 6 | Somnus Therapeutics Online entertainment arena offering diverse games, community features, and digital empowerment | $15M | 196 mo ago | 4 | Gary Cupit CEO | — | — |
| 7 | GenScript Provider of reagents and instruments for life sciences research | $15M | 204 mo ago | 5,260 | — | 11 patents Molecular biology tools for protein engineering, cloning, electrophoresis, and therapeutic protein stabilization | — |
| 8 | VyantBio Developer of drug discovery platform | $11M | 117 mo ago | 25 | — | — | — |
| 9 | Genomic Prediction Offers genomics tests for IVF health outcomes | $4M | 88 mo ago | 34 | Laurent Christian Asker Melchior Tellier CEO | — | — |
| 10 | Actinobac Biomed Developer of therapies for treating blood cancer, autoimmune diseases, and HIV | $4M | 96 mo ago | 3 | — | — | — |
| 11 | Abeille Pharmaceuticals Late-stage drug development company focusing on oncology and diabetes, with expertise in oral sustained… | $3M | 207 mo ago | — | Suresh Borsadia CEO & President | — | — |
| 12 | PharmaSeq Developer and markets p-Chip Micro transponders | $3M | 72 mo ago | 11 | — | 29 patents Optical transponder biosensors and combinatorial antibody diagnostics for DNA assembly. | — |
| 13 | Origin Developer of drug delivery platform for skin and soft-tissue infections | $2M | 32 mo ago | 7 | — | 148 patents Medical nitric oxide generation and delivery devices for therapeutic and diagnostic applications | — |
| 14 | Link Biosystems Developer of human pre‑clinical models and micro‑physiological systems for cancer drug development | $1M | 12 mo ago | — | Kacey Ronaldson-Bouchard Co-Founder & Chief Scientific Officer | — | — |
| 15 | Bar Harbor BioTech Developer of molecular biology products and services for life science research and clinical medicine | $995K | 135 mo ago | 7 | — | — | — |
| 16 | Chromocell Uses rare cells suited for effective high-throughput screening | $950K | 23 mo ago | 4 | Christian Kopfli CEO | 318 patents Fluorogenic oligo cell‑engineering assays and sweet‑taste/sodium‑channel therapeutic modulators | — |
| 17 | 3D Biotek Innovating 3D cell culture solutions for tissue engineering and drug discovery | $901K | 149 mo ago | 4 | Qing Liu Founder | 25 patents Scalable cell culture bioreactors with integrated scaffolding for tissue engineering | — |
| 18 | Generation Biotech Provider of targeted capture technology for DNA sequencing | $851K | 81 mo ago | — | Johannes Dapprich CEO | — | — |
| 19 | Visikol® Developer of optical clearing agent | $500K | 61 mo ago | 29 29 → 65 (+124%) | — | 7 patents Imaging and quantifying biomolecule penetration and calcium distribution in 3‑D tissue models | — |
| 20 | Genewiz Provider of a wide range of genomic services for the life sciences industry | $143K | 72 mo ago | 452 | Amy Liao Co-Founder & CEO | 6 patents High‑throughput DNA end‑sequencing, microbial ID kits, and ADP quantification assays. | — |
| 21 | Atheric Pharmaceutical Reformulated drugs for infectious diseases | $100K | 117 mo ago | — | Robert Malone Co-Founder & CEO | — | — |
| 22 | MicroSurfaces Surface coatings for biomedical industry | $100K | 218 mo ago | — | Athena Guo CEO & President | 5 patents Air‑stable lipid bilayer membranes for biosensors and composite coating methods for MEMS devices | — |
Top 12 Life Sciences Platforms and Tools companies in New Jersey
#1
Public · Freehold, New Jersey · founded 2016 · 6 employees$36.7Mraised▾
Avalon GloboCare is involved in developing exosome technology. They have developed core platforms, namely Avalon Cell and Avalon Rehab for early detection of oral cancer (saliva exosomes), ovarian cancer (plasma exosomes), kidney cancer (urine exosomes), skin regeneration, anti-fibrosis, treatments of degenerative disorders such as Alzheimer’s disease, arthritis, osteoporosis, etc.
- Feb 2026Post IPO$3.2M
- Oct 2023Post IPO$700K
- Dec 2022Post IPO$4M
- Sep 2019Conventional Debt$20M
#2
Public · Monmouth Junction, New Jersey · founded 1997 · 198 employees$22Mraised▾
Developer of hemoperfusion technology for removing toxins from the blood. It develops and manufactures therapeutic devices that purify the blood. Its purification technology is based on biocompatible, porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Each polymer bead contains millions of pores and channels that can be modified to remove substances as small as drugs, to substances as large as antibodies.
- Jan 2025Grant (prize money)$4.4M
- Sep 2022Grant (prize money)$288.3K
- Aug 2018Grant (prize money)$3M
- Aug 2018Grant (prize money)$2.6M
#3
Funding Raised · Irvington, New Jersey · founded 2021$1.2Mraised▾
Developer of human pre‑clinical models and micro‑physiological systems for cancer drug development. It focuses on generating immunocompetent tumoroid tissues and patient‑derived models that better mimic in‑vivo tumor biology.
- Jun 2025Grant (prize money)$327.8K
- Sep 2023Grant (prize money)$275.6K
- Sep 2023Grant (prize money)$275.4K
- Aug 2023Grant (prize money)$327.8K
#4
Public · North Brunswick, New Jersey · founded 2002 · 4 employees$949.9Kraised▾
Chromocell is focused on using rare cells ideally suited for effective high-throughput screening. It’s therapeutics pipeline is currently focused on analgesics and rare diseases, where Chromovert technology has proven highly effective in the rapid identification of potential new drug candidates. I
- Jul 2024Post IPO$750K
- May 2019Grant (prize money)$199.9K
#5
Acquired · Edison, New Jersey · founded 2002 · 54 employees$60Mraised▾
Transforming transplant medicine through innovative therapies and programs for healthcare providers. The company focuses on developing new therapies and programs to help transplant healthcare providers and the patients they treat. As a specialty pharmaceutical company, it is committed to improving the lives of transplant patients. The company develops medications utilized by transplant patients and patients with serious related diseases. Their lead transplant candidate is being developed as maintenance immunosuppression in kidney transplantation. They are focused on global development and commercialization. The company prides itself on providing an exceptional workplace environment for all employees, embracing diversity, and encouraging professional development.
- Feb 2018Conventional Debt$60M
#6
Acquired · Summit, New Jersey · founded 2017 · 7 employees$30.6Mraised▾
Engage Therapeutics is a clinical-stage biopharma developing an inhaled drug-device combo as rescue treatment for uncontrolled epileptic seizures. The Staccato is a handheld inhaler that administers the drug alprazolam and is intended as a "rescue treatment" like an EpiPen. The Staccato alprazolam combo was shown in a phase 2a trial to halt seizure-like activity in two minutes. Engage Therapeutics licensed the tech from Alexza Pharmaceuticals.
- Oct 2019Series A$7M
- Oct 2017Series A$23.6M
#7
Public · Parsippany Troy Hills, New Jersey · founded 2013 · 120 employees$27Mraised▾
Molecular diagnostics and pathology services for early cancer diagnosis and treatment. A life sciences company focused on providing complex molecular analysis. They offer clinically beneficial molecular diagnostic tests and pathology services, contributing to evidence-based approaches in healthcare. The company is dedicated to bringing insights to life through its diagnostic solutions. They operate in the life sciences industry, providing services for early diagnosis and treatment of cancer. Their offerings support physicians and patients in making informed decisions. They are committed to advancing the field of molecular diagnostics and pathology.
- Jul 2019Post IPO$27M
#8
Seed · Princeton, New Jersey · founded 2010 · 7 employees$1.9Mraised▾
Origin is involved in developing a drug delivery platform for skin and soft-tissue infections such as diabetic foot ulcers. They have developed a patented technology, IonoJet, which enables targeted delivery of nitric oxide (directly to treatment site), produced at the point of therapy from room air in a vehicle. Their products include IonoStim (for wound healing), Ionoderma (for onychomycosis), Ionosite (for arthritis and tendinitis), and Ionodent (for periodontitis and implantitis).
- Oct 2023Seed$51K
- Jun 2023Seed$500K
- May 2017Seed$1.3M
#9
Series A · Cherry Hill, New Jersey · founded 1999 · 25 employees$11.2Mraised▾
Developer of drug discovery platform. The company has an AnalytiX platform to identify drug candidates, targets, and biomarkers with the help of human biology and machine learning. The company is developing human disease models and drugs for multiple diseases.
- Sep 2016Series A$5.5M
- May 2016Series A$5M
- Apr 2009Grant (prize money)$600K
- Jul 2007Grant (prize money)$150K
#10
Series A · Bedminster, New Jersey · founded 2007 · 4 employees$15Mraised▾
Online entertainment arena offering diverse games, community features, and digital empowerment. A digital platform providing a wide array of online games, focusing on community building and user interaction. It offers a diverse selection of games, including sportsbooks, live casinos, slots, lottery, and poker, catering to various entertainment preferences. The platform emphasizes community engagement through social features and tournaments, fostering creativity, sportsmanship, and networking among players. It prioritizes user comfort and data security with encryption and verification processes. Beyond entertainment, it supports esports and digital content creators through competitions, workshops, and online training, empowering young talents in gaming and digital technology. It serves as a digital ecosystem that nurtures the growth of Indonesia's creative generation, offering a space for gaming, community interaction, and digital skill development. Features include login, registration, live chat, and promotions.
- Feb 2010Series A$15M
#11
Public · Piscataway, New Jersey · founded 2002 · 5260 employees$15Mraised▾
Provider of reagents and instruments for life sciences research. It provides a portfolio of services that include Bio-reagent, Bio-assay, lead optimization, and antibody drug development. Along with this, the company focuses on CRISPR reagents and reagents for CRISPR/CAS9 genome editing in particular. Additionally, the product line comprises several bioinformatics tools as well, such as the Molecular biology tool, Peptide tool, and protein tool.
- Jun 2009Series A$15M
#12
Series A · Monmouth Junction, New Jersey · founded 1999 · 11 employees$3Mraised▾
PharmaSeq develops p-Chip Micro transponders. The micro transponder tagged platform can be used in a range of fields for the object molecule tagging and tracking application. The technology applications include tagging, tracking and authenticating consumer goods, industrial goods, and small animals (lab mice), life science research, and clinical diagnostic markets.
- 2020Grant (prize money)$149.9K
- May 2019Grant (prize money)—
- 2017Grant (prize money)$301.2K
- Sep 2015Grant (prize money)—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in the United States
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 13,110 United States-affiliated papers.
- Harvard University633
- Broad Institute433
- Howard Hughes Medical Institute318
- Stanford University287
- Johns Hopkins University287
- Gene83→532
- Transcriptome25→436
- Genome117→419
- Disease6→218
- Immune system11→219
- Disease17→407
- Immune system4→266
- Gene38→281
- Transcriptome13→238
- Biomarker2→208
- Disease27→311
- Immune system6→152
- Cancer17→130
- Clinical trial4→111
- Biomarker2→92
Where bioinformatics is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing bioinformatics patents in the United States
United States bioinformatics patent filing is accelerating — 246 filings from 64 assignees (2016–2025), led by Edico Genome, Illumina, UNIV Washington; annual filings 22→23.
- Edico Genome129
- Illumina60
- UNIV Washington18
- Nantomics9
- Baluch Mohamed Khoso7
- Genomsys7
- Microsoft6
- Contamination Source Identificat5
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.